Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC

Inclusion Criteria:

* Newly diagnosed cytologically or histologically confirmed diagnosis of SCLC within 6 weeks before registration.
* Proven LD SCLC (CT thorax, abdomen, and bone scan (or PET/CT only) and brain MRI within 6 weeks before registration) according to the TNM classification version 7 that can be encompassed within a radical radiation port
* Only patients assessed by an interdisciplinary tumor board should be declared eligible taking into account eligibility for curative tRT and CHT according to NCCN Guidelines version 2.2014
* Karnofsky Index ≥ 60%
* Age at registration 18 to 75 years
* Normal bone marrow function: neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L
* Calculated creatinine clearance ≥ 60 mL/min is required if chemotherapy with cisplatin is scheduled. If cisplatin has to be replaced by carboplatin a creatinine clearance ≥ 50 mL/min is required
* Normal liver function: bilirubin ≤ 1 x ULN, AST and ALT ≤1.5 x ULN
* Fluency in either German, French or Italian
* Women are not breastfeeding. Women with child-bearing potential are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 6 months thereafter. A negative pregnancy test before inclusion (within 7 days) into the trial is required for all women with child-bearing potential. Men agree not to father a child during participation in the trial and during 6 months thereafter.
* Baseline QoL questionnaires FACT-Br and GHQ-12 have been completed within 14 days before registration
* Baseline NCF assessments have been completed within 14 days before registration:

  * HVLT-R
  * COWAT
  * TMT A
  * TMT B
* Patient must give written informed consent before registration

Exclusion Criteria:

* Previous malignancy within 5 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
* History of CNS metastases
* Prior brain RT
* History of RT to the thorax
* Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent, filling out QoL forms, participating in assessing NCF testing or interfering with compliance for oral drug intake.
* Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry.
* Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes).
* Any concomitant drugs contraindicated for use with the treatment drugs according to the approved product information.
* History of cerebrovascular disease or epilepsy requiring continuous treatment
* Symptomatic cardiac disease or a history of myocardial infarction within the previous 3 months
* Any psychological, familial or sociological/geographical conditions potentially hampering compliance with the study protocol and follow-up schedule
* Legal incapacity or limited legal capacity